A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2012
At a glance
- Drugs ASM 8 (Primary)
- Indications Asthma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Nov 2011 New source identified and integrated (European Clinical Trials Database).
- 23 Jun 2011 Planned initiation date (May 2013) added as reported by ClinicalTrials.gov.